Calgary, Alberta–(Newsfile Corp. – March 5, 2025) – Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) (“Hemostemix” or “HEM”), an autologous angiogenic stem cell therapy company that has safely treated 498 patients with various forms of cardiovascular disease, including peripheral arterial disease, chronic limb ischemia, non-ischemic dilated cardiomyopathy, ischemic cardiomyopathy, angina pectoris, congestive heart failure, and vascular dementia, announces the sale of 15 ACP-01 Therapy Convertible Debentures for proceeds of $517,230 USD, subject to TSXV Exchange approval.
“Since the beginning of the year, this adds up to revenue of 1,149,983 CAD, which is pleasing as it brings non-dilutive working capital to our company and its shareholders,” said Thomas Smeenk, CEO. “Importantly, the forward sales allow for planning both production and physician time in a very orderly manner. Additionally, forward sales enable an increase in production from 20 to 40 treatments per month and from 40 to 80 treatments per month from revenues. Assuming 20 treatments per month generate annual revenue of $8,880,000 USD ($12,876,000 CAD); assuming one physician performing four (4) blood draws per day generates 80 treatments per month (4 x $8,880,000 USD), shareholders can quickly understand how we can scale operations to our run rate as we announce additional forward sales and agreements with clinics and physicians worldwide,” Smeenk explained.
Each ACP-01 Therapy Convertible Debenture (“TCD”) is an unsecured obligation of Hemostemix Inc. and can be converted into an ACP-01 therapy on a first-purchase basis. Each TCD is transferable, disposable subject to a ROFR by Hemostemix, willable, and convertible into equity at the purchaser’s option. Each TCD bears interest at 6% per annum, payable annually in Hemostemix shares at the average closing price per share for the ten days prior to December 31 of each year. The TCDs may be admitted to trading on an exchange at a later date.
ABOUT HEMOSTEMIX
Hemostemix is an autologous stem cell therapy company founded in 2003. Awarded the World Economic Forum’s Technology Pioneer Award, the company has developed, patented, scaled, and sold autologous (patient’s own) blood-based stem cell therapies, including Angiogenic Cell Precursors (ACP-01), later Neural Cell Precursors (NCP-01), and Cardiomyocyte Cell Precursors (CCP-01). To date, Hemostemix has treated 498 patients, completed seven clinical trials involving 318 subjects, and published its results in nine peer-reviewed publications. ACP-01 is a safe, clinically relevant, and statistically significant treatment for Peripheral Arterial Disease, Critical Limb Ischemia, Non-Ischemic Dilated Cardiomyopathy, Ischemic Cardiomyopathy, Congestive Heart Failure, and Angina. Hemostemix has completed its clinical Phase II trial for Critical Limb Ischemia. For more information, please visit www.hemostemix.com.
For further information, please contact: Thomas Smeenk, President, CEO Co-Founder
EM: tsmeenk@hemostemix.com PH: 905-580-4170
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Forward-Looking Information: This press release contains “forward-looking information” within the meaning of applicable Canadian securities legislation. All statements herein that are not based on historical facts are forward-looking information. In particular, this press release contains forward-looking information regarding: the future sale of ACP-01, including the commercialization of ACP-01. There can be no assurance that such forward-looking information will prove to be accurate. Actual results and future events could differ materially from those anticipated in such forward-looking information. This forward-looking information reflects Hemostemix’s current beliefs and is based on information currently available to Hemostemix and on assumptions Hemostemix believes are reasonable. These assumptions include, but are not limited to: the underlying value of Hemostemix and its common shares; the results of ACP-01 research, trials, studies and analyses, including the analysis being equivalent to or better than previous research, trials or studies; the receipt of all required regulatory approvals for research, trials or studies; the level of activity, market acceptance and market trends in the healthcare sector; the economy generally; consumer interest in Hemostemix’s services and products; competition and Hemostemix’s competitive advantages; and obtaining satisfactory financing to fund Hemostemix’s operations including any research, trials or studies, and any litigation. Forward-looking information is subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of Hemostemix to be materially different from those expressed or implied by such forward-looking information. Such risks and other factors may include: Hemostemix’s ability to complete clinical trials, conduct satisfactory analysis, and submit results of these analyses to obtain regulatory approval for a Phase II or Phase III clinical trial of ACP-01; general business, economic, competitive, political, and social uncertainties; general capital market conditions and market prices for securities; delay or failure to receive board or regulatory approvals; actual results of future operations, including actual results of future research, trials, or studies; competition; changes in legislation affecting Hemostemix; timing and availability of external financing on acceptable terms; long-term capital requirements and future developments in Hemostemix’s markets and the markets in which the company intends to compete; lack of qualified, skilled labor or loss of key individuals; and risks related to the COVID-19 pandemic, including various recommendations, orders, and measures of governmental authorities trying to contain the pandemic, including travel restrictions, border closures, closure of non-essential businesses, service disruptions, quarantines, self-isolations, shelters-in-place and social distancing, disruptions to markets, economic activity and financing, supply chain disruptions and distribution channels, and a deterioration of general economic conditions including a possible national or global recession or depression; the potential impact of the COVID-19 pandemic on Hemostemix, which may include a reduced demand for services offered by Hemostemix; and a deterioration of financial markets that could limit Hemostemix’s ability to obtain external financing. A description of additional risk factors that could cause actual results to differ materially from forward-looking information can be found in Hemostemix’s disclosure documents on the SEDAR website at www.sedar.com. Although Hemostemix has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking information, there may be other factors that cause results not to be as anticipated, estimated, or intended. Readers are cautioned that the foregoing list of factors is not exhaustive. Readers are further cautioned not to place undue reliance on forward-looking information as there can be no assurance that the plans, intentions, or expectations upon which they are placed will occur. The forward-looking information contained in this press release is expressly qualified by this cautionary statement. The forward-looking information contained in this press release represents the expectations of Hemostemix as of the date of this press release and, accordingly, is subject to change after such date. However, Hemostemix expressly disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as expressly required by applicable securities law.
The original language (usually English) in which the original text is published is the official, authorized and legally valid version. This translation is provided for better understanding. The German version may be shortened or summarized. No responsibility or liability is assumed for the content, correctness, appropriateness or accuracy of this translation. From the translator’s point of view, the message does not constitute a buy or sell recommendation! Please note the English original message at www.sedarplus.ca, www.sec.gov, www.asx.com.au/ or on the company website!
